Author(s):
C. N. Hemalatha, N. Janani, S. Vanishree, N. Harikrishnan
Email(s):
hemalatha.pharm@drmgrdu.ac.in
DOI:
10.5958/0974-360X.2020.00524.7 
Address:
C. N. Hemalatha*, N. Janani, S. Vanishree, N. Harikrishnan
Faculty of Pharmacy, Dr. M. G. R. Educational and Research Institute Vellappanchavadi, Chennai-600077, Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 6,
Year - 2020
ABSTRACT:
HDACs regulate variety of cell functions. Several structurally distinct classes of HDAC inhibitor have been developed. Cutaneous T-cell lymphoma(CTCL) is a clinically and immunologically defined neoplasm which encompasses epidermotropic (mycosis fungoides, Sezary syndrome) and non-epidermotrepic variants. CTCL lymphoma comprises a heterogenous group of lymph proliferative disorders, characterised by clonal expansions of mature post thymic T-cells that infiltrate the skin. The USFDA have been approved many HDAC inhibitors such as Vorinostat, Romidepsin, Belinostat, Panobinostat in which the Vorinostat and Romidepsin has been approved for treatment of CTCL. The response rate shown in Histone deacetylase inhibitor in CTCL for Romidepsin was 34%-35%. Whereas the result of overall response rate of Vorinostat is 24%-30% in refractory advanced patients with CTCL. The impact on cell survival signalling varied with molecular phenotype this study suggests that cellular response to HDACs can be viewed as two distinct effect chromatin effect and a cell death effect. The divergent apoptotic responses observed reflect the variable clinical outcome of HDACi treatment. Romidepsin is potent inhibitors offers a promising new treatment for a disease with few existing therapies. We also found Romidepsin to be a more effective than Vorinostat. Our further objective was to further study the clinical benefits of Romidepsin in patients that had the best response of Stable Disease (SD).
Cite this article:
C. N. Hemalatha, N. Janani, S. Vanishree, N. Harikrishnan. Role of Histone Deacetylase (HDAC) Inhibitors for the Treatment of Cutaneous T-Cell Lymphoma (CTCL). Research J. Pharm. and Tech 2020; 13(6): 2963-2965. doi: 10.5958/0974-360X.2020.00524.7
Cite(Electronic):
C. N. Hemalatha, N. Janani, S. Vanishree, N. Harikrishnan. Role of Histone Deacetylase (HDAC) Inhibitors for the Treatment of Cutaneous T-Cell Lymphoma (CTCL). Research J. Pharm. and Tech 2020; 13(6): 2963-2965. doi: 10.5958/0974-360X.2020.00524.7 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-6-77
REFERRENCE:
1. Quina AS, Buschbeck M, Di Croce L. Chromatin structure and epigenetics. Biochem Pharmacol 2006; 72(11):1563-1569.
2. CETiffon, JEAdams, LvanderFits,SWen,PATownsend,AGanesan. The Histone deacetylase inhibitors Vorinostat and Romidepsin downmodulate IL-10 expression in cutaneous T-cell Lymphoma cells 2011; 162(7): 1590-1602.
3. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004; 91: 137–168.
4. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769–784.
5. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat. development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25:84–90.
6. Richon VM, Garcia-Vargas J, Hardwick JS. Development of vorinostat. current applications and future perspectives for cancer therapy. Cancer Lett 2009; 280: 201–210.
7. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834–840.
8. Victoria L. Luchenko, Thomas Litman, Arup R. Chakaraborty, Aaron Heffner, Christopher Devor, Julia Wilkerson. Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin 2014; 8: 1379-1392.
9. Glaser, K.B., Staver, M.J., Waring, J.F., Stender.J., Ulrich, R.G., Davidsen, S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition inT24 and MDA carcinoma cell lines Mol. Cancer Ther.2003; 2:151-163.
10. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6(1):38-51.
11. Piekarz, R.L., Frrye, R., Prince, H.M., Kirschbaum, M.H., Zain, J., Allen, S.L. Phase 2 trial of Romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 2011; 27:5410-5417.
12. Stephen Hanessian, Luciana Auzzas, Andreas Larsson, JianbinZhang, GiuseppeGiannini, GraziaGallo. Vorinostat-Like Molecules as Structural, Stereochemical, and Pharmacological Tools 2010; 1: 70–74.
13. Maisha Kelly Freeman, Pharm D, BCPS. Vorinostat and Romidepsin for the treatment of cutaneous T-cell lymphoma.2010; 35: 10-13.
14. Karen M VanderMolen, William McCulloch, Cedric J Pearce and Nicholas H Oberlies. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide). a natural product recently approved for cutaneous T-cell Lymphoma.2011; 64:525-531.
15. Richon VM. Cancer biology. Mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 2006; 95(S1):S2-S6.
16. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J ClinOncol 2010;28 (29):4485-4491.
17. Andrew Bodiford, Megan Bodge, Mahsa S Talbott, Nishitha M Reddy. Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma., 2014; 7:1971-1977.
18. Dickinson M, Ritchie D, Deangelo DJ, Spencer A, Ottmann OG, Fischer T. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Br J Haematol 2009; 147(1):97-101.
19. S.Dhanalakshmi, G. Sangeetha, K. Lokesh, U. Aleemasahada, Deng Arok deng. Review on cancer cell line studies. International Journal of Pharmaceutical Sciences and Research. 2016; 41(2): 220-224.